Wellington Management Co. LLP has recently announced that it has increased stake in Ascendis Pharma A/S (NASDAQ:ASND) by 3.47%. After grabbing 3.67 million shares, the institutional investor is now in possession of 0.12 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.58% having worth around $422.31 million. Moreover, Westfield Capital Management Co. increased its share by 0.12 million to have a control over 2.91 million shares. And Avoro Capital Advisor LLC raised its holdings to 0.57 million shares by acquiring 2.85 million shares or 5.11% of the stake.
Ascendis Pharma A/S (ASND) concluded trading on 11/23/22 at a closing price of $118.84, with 0.46 million shares of worth about $54.8 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 31.61% during that period and on Wednesday the price saw a loss of about -1.04%. Currently the company’s common shares owned by public are about 57.03M shares, out of which, 56.86M shares are available for trading.
Artisan Mid Cap Fund, T Rowe Price New Horizons Fund, and Janus Henderson Enterprise Fund are the top 3 mutual funds which are holding stakes in Ascendis Pharma A/S Artisan Mid Cap Fund is currently holding 1.37 million shares of worth totaling $158.01 million. The company recently came selling 39792.0 shares which brought its stake up to 2.46% of the company’s outstanding shares. T Rowe Price New Horizons Fund bought 46000.0 shares, after which its hold over company’s outstanding shares expand to 2.05%, leaving 1.14 million shares with the mutual fund that have a worth of about $131.42 million. Janus Henderson Enterprise Fund, after buying 1.0 million shares, have now control over 1.79% of the stake in the company. It holds 0.22 million shares of worth $114.93 million.
However, the stock later moved at a day high price of 122.80, or with a loss of -1.04%. Stock saw a price change of 3.47% in past 5 days and over the past one month there was a price change of 11.17%. Year-to-date (YTD), ASND shares are showing a performance of -11.66% which decreased to -19.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.58 but also hit the highest price of $148.80 during that period. The average intraday trading volume for Ascendis Pharma A/S shares is 466.41K. The stock is currently trading 1.63% above its 20-day simple moving average (SMA20), while that difference is up 6.93% for SMA50 and it goes to 17.04% higher than SMA200.
Wellington Management Co. LLP acquired 3.67 million shares of Ascendis Pharma A/S having value of about $422.31 million. Data submitted at the U.S SEC by Wellington Management Co. LLP revealed that the firm now holds 0.12 million shares in the company valued at close to $14627896.76, or have control over 3.47% stake in the company. Holding of mutual funds in the company is about 52.92% while other institutional holders and individual stake holders have control over 65.84% and — of the stake respectively.
The stock has a current market capitalization of $6.60B and its 3Y-monthly beta is at 0.53. It has posted earnings per share of -$8.87 in the same period. It has Quick Ratio of 6.80 while making debt-to-equity ratio of 1.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ASND, volatility over the week remained 4.28% while standing at 5.27% over the month.
Analysts are in expectations that Ascendis Pharma A/S (ASND) stock would likely to be making an EPS of -$2.51 in the current quarter, while forecast for next quarter EPS is -$2.61 and it is -$9.18 for next year. For the current quarter EPS, analysts have given the company a lowest target -$2.63 which is -$2.18 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.67 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 15.40% while it is estimated to increase by 100.00% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on October 20, 2022 offering a Buy rating for the stock and assigned a target price of $174 to it. Coverage by Berenberg stated Ascendis Pharma A/S (ASND) stock as a Buy in their note to investors on August 30, 2022, suggesting a price target of $166 for the stock. On March 28, 2022, Wedbush Resumed their recommendations, while on March 15, 2022, BofA Securities Upgrade their ratings for the stock with a price target of $161. Stock get a Buy rating from Citigroup on March 01, 2022.